Ocean State Clinical Coordinating Center
 Steven P. LaRosa, MD
Director of the OSCCC, Steven P. LaRosa, MD, is a member of the division of infectious diseases at Rhode Island Hospital and an assistant professor of medicine at Brown Medical School.
LaRosa was the lead clinical research physician for the successful phase III trial of recombinant human activated Protein C (Xigris TM), the first and only Food and Drug Administration-approved therapy that increases survival for adult patients with severe sepsis.
After accomplishing his undergraduate studies at Boston College and earning his medical degree from Boston University School of Medicine, LaRosa completed his internal medicine residency at the Cleveland Clinic Foundation and his infectious disease fellowship at Massachusetts General Hospital. LaRosa is board certified in internal medicine and infectious diseases.
Links to Published Research Abstracts:
- Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, for the PROWESS Sepsis Study Group. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. N Engl J Med 2001; 344 (10): 699-708.
- Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan B, Williams MD, Graham DE, Nelson DR, Levy H and Bernard G. Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated). Clin Infect Dis 2003;37:50-58.
- Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris, P, Schein R, Sollet, JP, Bates BM, Utterback BG, Maki D. The Clinical Evaluation Committee in a Large Phase 3 Trial of Drotrecogin Alfa (activated) in Patients with Severe Sepsis (PROWESS). Crit Care Med 2003;31:2291-2301
- LaRosa SP, Opal SM. Tissue Factor Pathway Inhibitor and Antithrombin Trial Results. Crit Care Clin 2005; 21:433-448
- LaRosa SP. Sepsis: menu of new approaches replaces one therapy for all. Cleve Clin J Med 2002; 69 (1): 65-73.
Back | OSCCC Physicians |
